A Phase III, Multicentre, Randomized Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab Paclitaxel Compared With Placebo With Nab Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer
This study is being conducted to determine the efficacy and safety in using Atezolizumab in
combination with nab-paclitaxel in treating participants with metastatic breast cancer. The
safety of single-agent nab-paclitaxel has been determined in previous studies of
participants with metastatic breast cancer, and preliminary data shows the use of
Atezolizumab is safe to use in combination with chemotherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society